Effect of Aliskiren on Progression of Coronary Disease in Patients With PrehypertensionThe AQUARIUS Randomized Clinical Trial

Effect of Aliskiren on Progression of Coronary Disease in Patients With PrehypertensionThe AQUARIUS Randomized Clinical Trial

Por: Stephen J. Nicholls, MBBS, PhD; George L. Bakris, MD; John J. P. Kastelein, MD, PhD; Venu Menon, MD4,; Bryan Williams, MD; Juergen Armbrecht, MD; Patrick Brunel, MD; Maria Nicolaides, MD; Amy Hsu, MS5; Bo Hu, PhD; Hui Fang, PhD; Rishi Puri, MBBS; Kiyoko Uno, MD, PhD; Yu Kataoka, MD, PhD; Dianna Bash, RN y  Steven E. Nissen, MD.  JAMA. 2013;310(11):1135-1144. doi:10.1001/jama.2013.277169.

The Aliskiren Quantitative Atherosclerosis Regression Intravascular Ultrasound Study (AQUARIUS) was a prospective, randomized, multicenter, double-blind clinical trial. Randomization was stratified according to geographic region.  Blood pressure reduction and renin-angiotensin-aldosterone system inhibition are targets for treatment of atherosclerosis. The effect of renin inhibition on coronary disease progression has not been investigated. To determine the effects of renin inhibition with aliskiren on progression of coronary atherosclerosis.